benefits to microdosing glp 1 GLP-1 for Thyroid Issues: Who Should Consider It? Microdosing GLP-1 Drugs: What To

Treatment should be continued only if there has been a beneficial metabolic response, typically defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight

By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide

Another author (YL) has received grants or contracts from the National Heart, Lung, and Blood Institute, the Patient-Centred Outcomes Research Institute, Sentara Research Foundation, and Novartis, outside the submitted work

doi: 10.1111/j.1742-7843.2009.00494.x 32 KildemoesHWSorensenHTHallasJ